Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
200 shown of 9,348 total abstracts
  1. Abstract 19632026-04-04 · 19:45 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-655
    M. Reck, G. Curigliano, H. Borghaei, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 17112026-04-05 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-703
    S. Peters, M. Reck, S. Modi, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 12112026-04-02 · 16:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-904
    M.C. Garassino, H. Rugo · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 10142026-04-01 · 14:15 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-125 study)
    M. Reck, L. Paz-Ares · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 18462026-04-01 · 16:30 CT · S100A
    MONARCH-243: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Saura, L. Paz-Ares · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 19072026-04-02 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-271 study)
    G. Curigliano, H. Rugo, S. Peters · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 16312026-04-03 · 16:00 CT · E450
    MONARCH-565: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M. Krop, C. Saura, T. Mok, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 17072026-04-04 · 14:30 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    H. Rugo, M. Reck · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 13012026-04-03 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-794 study)
    H. Rugo, M. Reck, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 12572026-04-04 · 19:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-695
    A. Spira, C. Saura, M. Reck, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 15112026-04-02 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-5
    M.C. Garassino, S. Peters, J. Cortes, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 18422026-04-02 · 16:45 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    C. Saura, S. Tolaney, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 18742026-04-01 · 21:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-785 study)
    C. Robert, M.C. Garassino, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 18162026-04-01 · 19:30 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    G. Curigliano, P. Schmid, A. Spira · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 14912026-04-02 · 18:15 CT · Hall B1
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-898
    H. Borghaei, C. Robert · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 11842026-04-01 · 15:15 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    C. Robert, T. Mok, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 11012026-04-05 · 18:45 CT · Arie Crown Theater
    DESTINY-Breast-387: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    J. Cortes, M.C. Garassino · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 15212026-04-04 · 15:30 CT · S100A
    PALOMA-520: Ibrance (palbociclib) maintenance in HR+ breast cancer
    F. Andre, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 14742026-04-03 · 21:45 CT · S406
    PALOMA-755: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    M.C. Garassino, P. Schmid, C. Robert · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 11362026-04-03 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-359 study)
    S. Tolaney, M.C. Garassino, F. Andre, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 15972026-04-01 · 16:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-908 study)
    S. Peters, M. Krop, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 16012026-04-02 · 19:00 CT · E450
    PALOMA-557: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    G. Curigliano, J. Brahmer · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 15322026-04-02 · 16:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-913
    E. Winer, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 19182026-04-01 · 16:45 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    C. Saura, S. Antonia · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 19652026-04-05 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-531 study)
    S. Antonia, C. Saura, J. Brahmer · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 11532026-04-02 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-875
    J. Cortes, S. Tolaney · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 12442026-04-05 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-203 study)
    M.C. Garassino, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 12382026-04-01 · 13:00 CT · E450
    MONARCH-815: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    H. Borghaei, J. Cortes, T. Mok · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 19072026-04-01 · 20:00 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-127 study)
    J. Cortes, M.C. Garassino, H. Rugo, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 17342026-04-03 · 13:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-38
    J. Cortes, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 11122026-04-05 · 21:15 CT · S100A
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-290
    G. Curigliano, C. Robert, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 18872026-04-05 · 18:30 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    A. Spira, S. Modi, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 12192026-04-05 · 19:30 CT · E450
    PALOMA-531: Ibrance (palbociclib) 1L in HR+ breast cancer
    S. Antonia, H. Rugo, P. Schmid · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 10792026-04-03 · 15:45 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-98
    S. Peters, S. Modi · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 10222026-04-04 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-414 study)
    M. Krop, M.C. Garassino, E. Winer, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 19032026-04-03 · 16:30 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-374 study)
    C. Saura, N. Rizvi, G. Curigliano, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 16122026-04-02 · 18:45 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    P. Schmid, M. Krop · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 13262026-04-04 · 16:30 CT · S406
    MONARCH-793: Verzenio (abemaciclib) 1L in HR+ breast cancer
    J. Brahmer, R. Herbst, M. Krop, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 12112026-04-03 · 16:00 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-693
    E. Winer, C. Robert, M. Krop · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 16702026-04-02 · 18:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    C. Robert, J. Brahmer, N. Rizvi, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 10102026-04-02 · 15:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-186 study)
    T. Mok, M. Krop, P. Schmid · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 15352026-04-05 · 19:00 CT · S100A
    DESTINY-Breast-102: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    M. Krop, M. Reck, C. Saura, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 19592026-04-05 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-605 study)
    H. Rugo, S. Peters · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 17402026-04-01 · 21:30 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-203
    E. Winer, N. Rizvi, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 19402026-04-05 · 18:00 CT · E450
    PALOMA-987: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    L. Paz-Ares, N. Rizvi, H. Rugo, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 12202026-04-03 · 13:45 CT · Hall B1
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-695
    H. Rugo, S. Modi, A. Spira, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 10542026-04-02 · 19:00 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Peters, L. Paz-Ares, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 11472026-04-05 · 16:00 CT · Hall B1
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-727
    M. Reck, T. Mok · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 14482026-04-05 · 14:45 CT · Arie Crown Theater
    PALOMA-775: Ibrance (palbociclib) maintenance in HR+ breast cancer
    A. Spira, P. Schmid, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 10512026-04-01 · 16:30 CT · S100A
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    P. Schmid, C. Saura, G. Curigliano · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 19802026-04-02 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-157
    S. Antonia, C. Robert, P. Schmid, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 15612026-04-01 · 20:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-48
    G. Curigliano, P. Schmid · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 10062026-04-04 · 13:00 CT · E450
    DESTINY-Breast-547: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    P. Schmid, F. Andre, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 12442026-04-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-63 study)
    P. Schmid, H. Borghaei, G. Curigliano · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 17232026-04-05 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-960 study)
    M. Krop, P. Schmid, J. Cortes · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 15582026-04-05 · 16:30 CT · E450
    OlympiA-692: Lynparza (olaparib) 1L in HR+ breast cancer
    F. Andre, C. Saura, H. Rugo, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 18482026-04-01 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-601
    L. Paz-Ares, M.C. Garassino · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 19782026-04-04 · 19:30 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-105
    M.C. Garassino, M. Reck, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 14562026-04-04 · 15:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-75
    P. Schmid, J. Cortes, R. Herbst, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 16302026-04-02 · 19:00 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-190
    S. Tolaney, F. Andre, M. Krop, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 11292026-04-01 · 15:30 CT · S406
    MONALEESA-468: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    M.C. Garassino, C. Saura, S. Modi · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 18472026-04-05 · 14:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-729
    M.C. Garassino, L. Paz-Ares · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 14452026-04-02 · 18:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-319
    P. Schmid, G. Curigliano, F. Andre, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 10502026-04-01 · 14:45 CT · Arie Crown Theater
    PALOMA-887: Ibrance (palbociclib) 2L in HR+ breast cancer
    M. Reck, C. Saura, J. Brahmer, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 17002026-04-02 · 13:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-153 study)
    H. Rugo, F. Andre, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 17812026-04-04 · 18:00 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-712
    L. Paz-Ares, M. Reck · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 17792026-04-01 · 18:00 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    S. Tolaney, F. Andre · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 12182026-04-03 · 20:30 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    G. Curigliano, H. Rugo, S. Tolaney · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 11542026-04-03 · 20:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-569
    N. Rizvi, C. Saura, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 15082026-04-05 · 18:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-815 study)
    F. Andre, T. Mok, L. Paz-Ares, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 16712026-04-04 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-284 study)
    T. Mok, S. Antonia, S. Tolaney · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 17512026-04-03 · 14:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-252
    S. Antonia, M.C. Garassino, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 14822026-04-02 · 16:30 CT · S406
    Quality of life outcomes with Keytruda in patients with TNBC
    H. Rugo, S. Modi, S. Peters · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 11492026-04-01 · 14:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-796 study)
    C. Robert, R. Herbst, E. Winer · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 15442026-04-03 · 19:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-134 study)
    G. Curigliano, E. Winer, F. Andre, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 13412026-04-04 · 18:45 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-591
    S. Modi, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 13122026-04-02 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-162
    R. Herbst, L. Paz-Ares, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 17322026-04-02 · 21:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-199
    J. Cortes, M. Krop, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 13682026-04-05 · 14:30 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    N. Rizvi, H. Rugo, S. Modi · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 14182026-04-04 · 13:45 CT · Hall B1
    ASCENT-457: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    H. Borghaei, E. Winer, L. Paz-Ares · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 17782026-04-01 · 19:00 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-902
    J. Brahmer, A. Spira, L. Paz-Ares · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 12572026-04-05 · 18:30 CT · Arie Crown Theater
    ASCENT-357: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    G. Curigliano, J. Cortes, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 16662026-04-05 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-648
    S. Modi, J. Brahmer · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 15652026-04-01 · 16:00 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-50
    S. Tolaney, L. Paz-Ares, J. Brahmer, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 11372026-04-03 · 16:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-167
    S. Modi, E. Winer, C. Robert · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 18992026-04-03 · 16:45 CT · Hall B1
    ASCENT-42: Trodelvy (sacituzumab govitecan) 2L in TNBC
    F. Andre, G. Curigliano, M.C. Garassino · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 14122026-04-05 · 16:15 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    T. Mok, H. Rugo, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 16652026-04-02 · 18:45 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-269
    T. Mok, S. Antonia · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 11172026-04-01 · 20:30 CT · S100A
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-189
    C. Saura, C. Robert, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 18922026-04-03 · 16:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-501
    F. Andre, P. Schmid · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 16382026-04-03 · 15:30 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-751
    T. Mok, R. Herbst, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 19422026-04-03 · 13:00 CT · S406
    OlympiA-432: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    H. Rugo, J. Brahmer, F. Andre, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 15032026-04-05 · 16:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-799
    L. Paz-Ares, P. Schmid, S. Antonia, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 12512026-04-02 · 16:30 CT · Hall B1
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-44
    S. Antonia, J. Brahmer, S. Modi · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 17302026-04-04 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-578 study)
    S. Modi, A. Spira, H. Borghaei · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 16552026-04-04 · 14:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-405
    J. Brahmer, N. Rizvi, S. Modi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 16282026-04-05 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-421 study)
    R. Herbst, E. Winer, F. Andre, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 16622026-04-01 · 20:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-395 study)
    T. Mok, S. Tolaney, F. Andre · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 19262026-04-03 · 16:30 CT · E450
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-139
    M.C. Garassino, C. Saura, C. Robert, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 11912026-04-04 · 16:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-783
    H. Borghaei, H. Rugo, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 12902026-04-03 · 20:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-415
    A. Spira, S. Tolaney, M. Reck · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 10122026-04-05 · 18:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-30
    F. Andre, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 14322026-04-01 · 16:15 CT · E450
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-273
    N. Rizvi, M. Reck, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 13992026-04-02 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-861
    M. Krop, E. Winer, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 10182026-04-01 · 19:15 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-353
    N. Rizvi, R. Herbst, F. Andre · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 13602026-04-01 · 20:15 CT · Arie Crown Theater
    MONALEESA-72: Kisqali (ribociclib) maintenance in HR+ breast cancer
    P. Schmid, N. Rizvi · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 19432026-04-02 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda adjuvant for TNBC: KEYNOTE-455
    H. Borghaei, R. Herbst, G. Curigliano, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 15722026-04-04 · 14:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-813
    J. Brahmer, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 16122026-04-05 · 18:30 CT · Arie Crown Theater
    DESTINY-Breast-861: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    E. Winer, R. Herbst · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 16582026-04-05 · 16:45 CT · E450
    MONARCH-960: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M.C. Garassino, S. Peters, S. Antonia, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 10372026-04-05 · 16:00 CT · S406
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-860
    S. Antonia, L. Paz-Ares, C. Saura · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 18732026-04-03 · 14:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-932
    H. Rugo, M.C. Garassino, S. Peters, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 13452026-04-05 · 15:45 CT · Hall B1
    PALOMA-986: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    R. Herbst, H. Rugo, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 15252026-04-05 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-548
    M. Reck, J. Brahmer, H. Rugo, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 11942026-04-04 · 21:30 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-728
    H. Borghaei, L. Paz-Ares · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 14012026-04-04 · 21:45 CT · S100A
    OlympiA-790: Lynparza (olaparib) 3L+ in HR+ breast cancer
    H. Rugo, C. Saura · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 18982026-04-04 · 13:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-685
    G. Curigliano, S. Tolaney, L. Paz-Ares, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 14112026-04-02 · 21:30 CT · E450
    MONALEESA-340: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    R. Herbst, N. Rizvi · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract 14612026-04-01 · 14:15 CT · S100A
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-399
    A. Spira, S. Antonia, E. Winer, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 16112026-04-02 · 14:45 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-653
    S. Modi, F. Andre · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 14252026-04-05 · 19:30 CT · S406
    PALOMA-637: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Robert, G. Curigliano · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 11292026-04-01 · 18:15 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-549
    J. Brahmer, H. Rugo, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 18592026-04-03 · 13:15 CT · Arie Crown Theater
    ASCENT-40: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    S. Antonia, E. Winer, C. Robert, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 10852026-04-01 · 13:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-11
    S. Peters, R. Herbst, J. Cortes, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 14482026-04-03 · 14:45 CT · S100A
    ASCENT-403: Trodelvy (sacituzumab govitecan) 2L in TNBC
    M. Reck, S. Tolaney, H. Borghaei · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 19602026-04-03 · 21:15 CT · S100A
    MONALEESA-375: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    N. Rizvi, J. Cortes, S. Modi · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 10432026-04-02 · 14:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-179 study)
    N. Rizvi, F. Andre, E. Winer, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 14752026-04-05 · 18:00 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-843
    A. Spira, N. Rizvi, C. Saura · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 19362026-04-01 · 18:45 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-660
    R. Herbst, L. Paz-Ares · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 12862026-04-03 · 18:15 CT · S406
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-307
    H. Rugo, J. Cortes, M. Reck · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 18242026-04-05 · 21:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-248 study)
    J. Brahmer, E. Winer, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 16562026-04-05 · 14:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-978
    A. Spira, M.C. Garassino, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 16622026-04-02 · 19:45 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-796
    S. Modi, F. Andre, H. Rugo · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 10452026-04-05 · 20:30 CT · E450
    ASCENT-848: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    M. Reck, F. Andre, P. Schmid, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 11782026-04-01 · 14:30 CT · S100A
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-790
    E. Winer, R. Herbst, F. Andre · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 12282026-04-03 · 13:15 CT · Hall B1
    PALOMA-859: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    P. Schmid, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 18772026-04-03 · 15:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-586
    S. Tolaney, N. Rizvi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 10402026-04-01 · 16:45 CT · Hall B1
    MONARCH-358: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    P. Schmid, S. Antonia, M. Reck · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 10222026-04-01 · 19:00 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-377
    R. Herbst, C. Saura · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 10652026-04-01 · 21:15 CT · Hall B1
    MONARCH-873: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    M. Krop, S. Antonia · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 14552026-04-04 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-600 study)
    G. Curigliano, E. Winer, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 10162026-04-02 · 20:30 CT · S100A
    ASCENT-654: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    S. Antonia, S. Peters, M. Krop · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 19002026-04-03 · 21:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-938 study)
    S. Tolaney, S. Antonia, J. Cortes, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 11032026-04-05 · 13:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-882
    E. Winer, N. Rizvi, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 15152026-04-04 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-719 study)
    J. Cortes, M. Reck, T. Mok, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 13782026-04-04 · 21:45 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-16
    F. Andre, R. Herbst, M. Reck, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 16642026-04-03 · 19:00 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-299
    P. Schmid, H. Rugo, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 17692026-04-04 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-14 study)
    J. Cortes, C. Saura, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 19312026-04-02 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-969 study)
    H. Borghaei, J. Brahmer, P. Schmid · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 10452026-04-04 · 19:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-619
    C. Saura, N. Rizvi, M. Krop, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 13952026-04-03 · 14:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-264
    S. Antonia, S. Modi, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 13102026-04-03 · 19:30 CT · Arie Crown Theater
    MONALEESA-465: Kisqali (ribociclib) 1L in HR+ breast cancer
    S. Peters, M. Reck, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 10312026-04-04 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-172 study)
    N. Rizvi, H. Borghaei, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 18032026-04-03 · 18:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-643 study)
    G. Curigliano, E. Winer, M.C. Garassino, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 10382026-04-01 · 21:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-432
    S. Modi, H. Rugo, P. Schmid, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 15702026-04-03 · 14:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-950 study)
    L. Paz-Ares, C. Saura · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 18812026-04-03 · 19:30 CT · S406
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-843
    C. Saura, G. Curigliano, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 19652026-04-04 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-963 study)
    N. Rizvi, A. Spira, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 10872026-04-04 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-961 study)
    E. Winer, L. Paz-Ares, S. Modi · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 15992026-04-01 · 14:45 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-105
    C. Saura, H. Rugo, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 15672026-04-05 · 13:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-334 study)
    E. Winer, S. Antonia, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 14082026-04-02 · 14:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-673
    M. Krop, N. Rizvi, S. Modi · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 19082026-04-04 · 19:00 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-343
    N. Rizvi, L. Paz-Ares · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 10772026-04-02 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-297
    M.C. Garassino, R. Herbst · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 14012026-04-03 · 18:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-203
    S. Antonia, M. Reck, M. Krop · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 12332026-04-02 · 18:45 CT · S406
    ASCENT-384: Trodelvy (sacituzumab govitecan) 1L in TNBC
    M.C. Garassino, A. Spira, C. Robert, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 12602026-04-04 · 15:00 CT · E450
    ASCENT-594: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    F. Andre, C. Robert · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 14082026-04-02 · 20:15 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-914
    C. Robert, L. Paz-Ares, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 14132026-04-02 · 16:15 CT · Arie Crown Theater
    KEYNOTE-230: Keytruda (pembrolizumab) 3L+ in TNBC
    L. Paz-Ares, T. Mok, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 13752026-04-01 · 16:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-259 study)
    N. Rizvi, S. Antonia, C. Robert, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 16152026-04-01 · 21:00 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-859
    S. Peters, H. Borghaei, C. Saura · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 19992026-04-02 · 16:30 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-52
    C. Robert, M.C. Garassino · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 11012026-04-05 · 15:15 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-602
    R. Herbst, J. Cortes · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 13812026-04-05 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-943
    T. Mok, L. Paz-Ares, S. Antonia, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 13252026-04-03 · 16:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-122
    L. Paz-Ares, M.C. Garassino, F. Andre · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 17952026-04-02 · 15:00 CT · Arie Crown Theater
    OlympiA-451: Lynparza (olaparib) maintenance in HR+ breast cancer
    T. Mok, E. Winer, S. Modi · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 14222026-04-01 · 20:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-355 study)
    F. Andre, C. Saura · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 18412026-04-02 · 21:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-822 study)
    S. Antonia, P. Schmid · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 17052026-04-03 · 15:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-687 study)
    J. Brahmer, M. Krop, S. Antonia, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 17872026-04-05 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-587
    S. Peters, C. Saura · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 10322026-04-01 · 18:15 CT · S406
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-199
    E. Winer, P. Schmid, M. Krop · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 16342026-04-05 · 20:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-86
    S. Peters, A. Spira, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 16412026-04-05 · 13:00 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-322
    E. Winer, M. Krop, J. Brahmer · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 18872026-04-02 · 20:15 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-550
    S. Modi, G. Curigliano, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract 16882026-04-03 · 19:45 CT · S100A
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-655
    C. Saura, M. Reck, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 19442026-04-04 · 14:30 CT · S406
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-303
    H. Borghaei, S. Antonia · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 14862026-04-04 · 16:30 CT · S100A
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-649
    R. Herbst, G. Curigliano, C. Robert, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 19692026-04-03 · 18:15 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-742
    T. Mok, A. Spira, J. Brahmer, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 11832026-04-03 · 20:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-635
    S. Modi, M.C. Garassino · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 15302026-04-02 · 21:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-692
    S. Tolaney, L. Paz-Ares · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  191. Abstract 13452026-04-02 · 20:15 CT · E450
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-836
    N. Rizvi, C. Robert, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  192. Abstract 10202026-04-02 · 15:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-646
    F. Andre, L. Paz-Ares, N. Rizvi · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 16382026-04-01 · 21:15 CT · S100A
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-679
    S. Modi, N. Rizvi, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 17262026-04-04 · 16:00 CT · S100A
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-153
    C. Robert, G. Curigliano, H. Borghaei, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 17142026-04-01 · 16:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-707 study)
    S. Peters, H. Rugo, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 12252026-04-05 · 13:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-361
    L. Paz-Ares, A. Spira, M.C. Garassino · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 13312026-04-04 · 19:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-159
    G. Curigliano, H. Rugo, M. Krop · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  198. Abstract 11862026-04-04 · 13:15 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-349
    P. Schmid, G. Curigliano, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 11732026-04-02 · 19:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-131
    C. Robert, M.C. Garassino, N. Rizvi · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 11182026-04-03 · 16:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-927
    S. Peters, M. Krop, T. Mok · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.